@entity3812 in the treatment of XXXX .

@entity1 @entity82 @entity3812 @entity1575 @entity7160
There is preliminary evidence that @entity3812 , an inhibitor of collagen synthesis, may be beneficial in the treatment of @entity1575 . To evaluate the use of @entity3812 (1 mg per day, five days per week) in the treatment of @entity1575 , we performed a randomized, double-blind, placebo-controlled trial in which 100 @entity1 were followed for up to 14 years. Forty-five @entity1 had @entity7160 , 41 had @entity82 , and the remaining 14 had @entity82 with various other causes. Histologic studies were available for 92 percent of @entity1 . Seventy-three @entity1 were in @entity1 -Turcotte class A, 26 were in class B, and one was in class C. Fifty-four @entity1 received @entity3812 , and 46 received placebo. The overall survival in the @entity3812 group was markedly better than in the placebo group (median survival, 11 and 3.5 years, respectively; P less than 0.001). The cumulative 5-year survival rates were 75 percent in the @entity3812 group and 34 percent in the placebo group; the corresponding 10-year survival rates were 56 percent and 20 percent. Among the 30 @entity1 treated with @entity3812 who underwent repeated liver biopsies, histologic improvement was seen in 9; the liver appeared normal in 2, and 7 had minimal portal @entity82 . No histologic improvement was observed in the 14 members of the placebo group who had two or more biopsies. Few side effects were observed in either group.
